86% of Dexcomusers still use the product after one year.21

CGM lowers A1Cregardless ofinsulin deliverymethod.19,20

With insulin costs tripling over the last five years,7 stakeholders are looking

for care management solutions that will reduce both medical and pharmacy

costs and deliver consistent outcomes. The Dexcom Continuous Glucose

Monitoring (CGM) System helps unlock cost and care e�ciencies.

Informed care decisions. CGM users adjust their insulin more frequently, resulting in A1C reductions.6,8

CGM rate of change (ROC) arrows were the driving factor in insulin dose

adjustment and insulin optimization.**6

CGM insight helps members stay in control9 and can reduce costly interven-

tions by reducing severe hypoglycemia for insulin dependent members by

as much as 41%.

CGM improved 29 indices of glycemic control.12$1,169

Estimated PMPY mean savingsfor reduction in A1C of 1%.5

** The Dexcom G5 Mobile GCM System does not replace a blood glucose meter. Always use the values from your blood glucose meter for treatment decisions.

Multiple Daily Injection (MDI), Continuous Subcutaneous Insulin Infusion (CSII).

† Average annual direct medical costs savings for patients with an A1C less than 7% compared to a matched sample of patients with A1c greater than or equal 7%. ‡ Compared to traditional SMBG.

-50% of typical correction dose MDI

-37% of typical correction dose CSII

-52% of typical correction dose MDI

-38% of typical correction dose CSII

+146% of typical correction dose MDI

+138% of typical correction dose CSII

50% reduction of typical insulin correction dosein response to CGM stable arrow.*6

20% reduction in cardiovascular risk by

reducing A1C (7.2 vs. 8.0).4

In control equates to better outcomes. Average PMPY savings for members in control (A1C of <7%) is $2,713.†12 CGM

dramatically improved 29 indices of glycemic control and glycemic variability.‡13

• Lowers A1C without the increased risk of hypoglycemia risk14,15

• CGM users across all ages have lower A1C16

• Increases time in ideal target range4

A complete care management solution.CGM delivers many of the benefits of complex care management programs,17

but with greater cost transparency and ease of deployment.

• Improve knowledge: Delivers passive and continuous results (up to 288

readings every 24 hours) for greater glucose awareness

• Build confidence: 90% of Dexcom users feel CGM gives them the

confidence to e�ectively manage their diabetes18

• Enhanced self-management skills: CGM users adjust their insulin more

frequently, resulting in A1C reductions8

• Stablized lab values: CGM use for ≥48 days reduced A1C by 1.2%14

40035030025020015010050

CGM members spend 26%more time in ideal targetzone (81-140mg.dl)10

CGM reduces time spent hyperglycemic (≥240mg/dl)by 23%10

CGM reduces time spent hypoglycemic (≤60mg/dl)by 48%10,11

*MDI patients.

C

M

Y

CM

MY

CY

CMY

K

LBL014279 - Cost of Poor Diabetes Control Hres.pdf 1 9/28/16 7:32 PM

The vast majority of members with diabetes have an A1C above ADA and

HEDIS targets,2 putting them at risk for other costly comorbidities including

hyperlipidemia3 and cardiovascular disease.4 Despite the advances in

diabetes treatment and technologies over 20 years, the percentage of

patients at the A1C target of ≤ 7% has actually remained flat at 34%.2

Is it time to rethink strategies and investments around

diabetes care management?

Percentage of patients above ADA A1C target of ≤7%.2

The cost of poor diabetes control.

$44.1BAnnual cost of medications to treat the complications of diabetes.1

66%

6340 Sequence DriveSan Diego, CA 92121(858) 200-0200www.dexcom.com

LBL014279 Rev 001

1 American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2012. Diabetes Care 2013 Apr; 36(4): 1033-1046.

2 Selvin E, Parinello CM, Daya N, Bergenstal RM Trends in Insulin Use and Diabetes Control in the U.S.: 1988–1994 and 1999–2012. Diabetes Care. Diabetes Care, November 2015.

3 Snipelisky D, Ziajka P. Diabetes and hyperlipidemia: A direct quantitative analysis. World Journal of Cardiovascular Diseases, 2012, 2, 20-25.

4 Nathan D, Cleary PA, Backlund JC, Genuth SM, et al. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. N Engl J Med 2005;353:2643-53.

5 Grabner M, Abbott S, Nguyen M, Chen Y, Quimbo R. Estimated Cost Savings Associated with A1c Reductions in a Large US Commercial Health Plan. Value in Health (Impact Factor: 3.28. -5/2013; 16(3):A160.

6 Pettus J, Edelman S. Use of Glucose Rate of Change Arrows to Adjust Insulin Therapy Among Individuals with Type 1 Diabetes Who Use Continuous Glucose Monitoring. Diabetes Technology & Therapuetics, Volume 18, Supplement 2, 2016.

7 Hua X, Carvalho N, Tew M, Huang ES, Herman WH, Clarke P. Expenditures and Prices of Antihyperglycemic Medications in the United States: 2002-2013. JAMA. 2016;315(13):1400-1402. doi:10.1001/jama.2016.0126.

8 Battelino T, Conget I, Olsen B, et al. The use and e�cacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012;55:3155-3162 727-23.

9 Bode B, Beck RW, Xing D, Gilliam L, Hirsch I, et al. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Sustained benefit of continuous glucose monitoring on A 1c, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care 32:2047–2049.

10 Garg S, Zizzer H, Schwartz S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006 Jan;29(1):44-50.

11 Beck RW, MD, Hirsch IB, La�el L, Tamborlane WV, et al. E�ect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes. Diabetes Care. 2009 August; 32(8): 1378–1383.

12 Juarez DT, Goo R, Tokumaru S, et al. Association Between Sustained Glycated Hemoglobin Control and Healthcare Costs” Am J Pharm Benefits 2013; 5(2):59-64.

13 Rodbard D, Bailey T, Jonvanovic L, et al. Improved Quality of Glycemic Control and Reduced Glycemic Variability with Use of Continuous Glucose Monitoring. DIABETES TECHNOLOGY & THERAPEUTICS Volume 11, Number 11, 2009.

14 Ehrhardt NM, Chellappa M. The E�ect of Real-Time Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Mellitus J Diabetes Sci Technol 2011;5(3):668-675 CGM:.

15 JDRF Continuous Glucose Monitoring Study Group. N Engl J Med. 2008;359(14):1464-1476.

16 T1D Exchange, April 2015.

17 Care Continuum Alliance (formerly the Disease Management Association of America).

18 Polonsky WH, Hessler, D. What are the Quality of Life-Related Benefits and Losses Associated with Real-Time Continuous Glucose Monitoring? A Survey of Current Users. Diabetes Technology and Therapeutics Vol 15, No 4, 2013.

19 Bergenstal RM, et al. N Engl J Med. 2010;363: 311-320.

20 Miller KM, et al. Diabetes Care. 2015;38:971-978.

21 Dexcom Internal Data on File, 2014.

The Dexcom G5 Mobile GCM System does not replace a blood glucose meter. Always use the values

from your blood glucose meter for treatment decisions.

A smart device is not included with the Dexcom G5 Mobile CGM System. For a list of compatible smart

devices see www.dexcom.com/faq/what-devices-and-software-are-compatible-dexcom-cgm-apps.

©2016 Dexcom Inc. All rights reserved. This product is covered by US patent. DEXCOM, DEXCOM G4,

DEXCOM G4 PLATINUM, ONE STEP AHEAD are trademarks and registered trademarks of Dexcom, Inc.

All trade dress used in connection with Dexcom products and services appearing herein are property

of Dexcom and protected by the United States and foreign trademark laws.

BRIEF SAFETY STATEMENT: The Dexcom G5 Mobile Continuous Glucose Monitoring System (the “System”) is a glucose monitoring system indicated for detecting trends

and tracking patterns in persons (age 2 years and older) with diabetes. CONTRAINDICATIONS: Remove the System (sensor, transmitter, and receiver) before Magnetic

Resonance Imaging (MRI), Computed Tomography (CT) scan, or high-frequency electrical heat (diathermy) treatment. The System is MR Unsafe. Do not bring any portion

of the System into the MR environment. Taking acetaminophen while wearing the sensor may falsely raise your sensor glucose readings. WARNING: Do not use the System

for treatment decisions. The System does not replace a blood glucose meter. The System is not approved for use in pregnant women, persons on dialysis or critically ill

persons. If a sensor breaks and no portion of it is visible above the skin, do not attempt to remove it. Seek professional medical help if you have infection or inflammation.

Report broken sensors to Dexcom Technical Support. Sensor placement is not approved for sites other than under the skin of the belly (ages 2 years and older) or upper

buttocks (ages 2-17 years). Your smart device’s internal settings override your Dexcom app settings. Accessory devices (like a smart watch) might override your smart

device’s alert and notification settings. The Share feature must be turned “On” with an active internet connection to communicate glucose information to a Follower. The

Follower must download and install the Dexcom Follow App onto a separate smart device with an active internet connection to receive data. Contact Dexcom Toll Free

at 877-339-2664 or www.dexcom.com for detailed indications for use and safety information.

C

M

Y

CM

MY

CY

CMY

K

LBL014279 - Cost of Poor Diabetes Control out.pdf 1 9/28/16 7:30 PM